HCL and UpLink Call for Applications Globally for Second Challenge of Aquapreneur Innovation Initiative
21.8.2023 15:24:00 EEST | Business Wire | Press release
HCL, a global conglomerate and UpLink, the open innovation platform of the World Economic Forum, announced opening the applications for the Zero Water Waste Challenge – part of the Aquapreneur Innovation Initiative. The challenge calls for innovative water usage approaches to improve freshwater conservation from supply to demand, moving towards zero water waste. At the end of the challenge, 10 winners will receive a total financial award of 1.75M CHF.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230821935081/en/
|
Important Dates to Note |
|
|
21 August to 2 October 2023 |
Open for submissions |
|
17 October to 15 November 2023 |
Review and selection process |
|
January 2024 |
Announcement of the winning Top Innovators |
This is the second challenge out of five Challenges of the HCL and UpLink’s Aquapreneur Innovation Initiative. Launched last year at Davos in May 2022, to create a first-of-its-kind innovation ecosystem for the global freshwater sector. The last date to apply for the second-year challenge is October 2nd, 2023. Full details and eligibility criteria can be found at this link. Under this initiative HCL committed $15 million until 2027 to support the water-focused entrepreneurs.
Roshni Nadar Malhotra, Chairperson, HCLTech said, “ As the climate change continue to intensify and fresh-water resources become scarcer, the corporates have a unique opportunity to make a substantial difference in the world we live in. At HCL, we are committed to help resolve this global crisis. In partnership with UpLink, we are all set to announce the second edition of our Aquapreneur Innovation Initiative moving towards zero water waste. While our commitment to this vital cause is unwavering, we invite fellow organizations to join us in this shared mission, contributing essential funding and catalyzing widespread exposure.”
Gim Huay Neo, Managing Director of the Centre for Nature and Climate at the World Economic Forum said, “ The Aquapreneur Innovation Initiative is building a vibrant innovation ecosystem for water which is crucial for the conservation and restoration of all-natural ecosystems. By connecting innovators, experts, investors and partners, this initiative is fast-tracking high-impact solutions to enhance water security. Already, we’re seeing significant impact with the ten winners of the first Innovation Challenge and we’re excited to surface and support a new cohort of aquapreneurs .”
The focus of this year’s challenge will be on:
- Capturing and protecting freshwater supply
Protecting groundwater reservoirs by capturing additional water resources. Solutions could focus on recharging groundwater, capturing storm- and rainwater or water from the atmosphere, preventing or minimizing leakages, boosting ecosystem resilience or monitoring and managing freshwater.
- Water re-use and recycling of materials
Increase water-efficiency by reusing and recycling water resources. Solutions could include products that enable shower, washing machine and sink water to be recycled for non-potable uses, or reuse of water in industrial facilities, cleaner and greener tech to purify reused water, etc. Ideally need to manage trade-offs, e.g. need to have sustainable energy support, as well as focus on water quality.
- Saving water in agriculture
Reduce water withdrawal in agriculture through smart irrigation. Solutions could include precision irrigation, remote sensing, regenerative agricultural practices focused on water retention, and technologies such as mobile applications to optimize the amount and timing of water applied to crops.
Evaluation and selection criteria for 2nd year will include:
I. Organizational structure
- Financially viable business model: solution demonstrates a sustainable business model and revenue approach, and presents proof of funding history, as well as investable opportunities for investors or philanthropic funders.
- Stage: beyond the ideation phase and demonstrating the potential to scale and achieve long-term financial viability, impact, and sustainability. UpLink Top Innovators have typically reached the pilot to growth/scale phase of their operations.
- Management team: committed, diverse and values driven management team with the right skillset and demonstrated execution capabilities, and including local staff, or the willingness to work with local stakeholders.
- Measurement and standards verification: solution demonstrates a clear impact monitoring, evaluation, and verification framework. The metrics and indicators should be tracked transparently, reference and apply relevant, robust standards, and receive independent credentialing and third-party verification.
- Governance and operating models: solution has a legal entity attached to the project or technology. The operating model shows the extent to which the project has achieved financial viability and sustainable revenue streams or has a vision and plan for achieving it.
II. Key characteristics:
- Innovative: while many water technologies already exist, innovation is needed in service, pricing, partnerships, and business models.
- Replicability: submissions from across the globe that are scalable in their local contexts and potentially replicable in different parts of the world.
- Holistic and sustainable impact: solution demonstrates ‘win-win’ benefits for multiple agendas, particularly society and the environment. Solution supports the water agenda in the long term, delivering impact that outlasts the length of the challenge.
- External risk: solution is aware of any risks and uncertainties associated with achieving the desired outcomes.
Top 10 water-focused entrepreneurs will be selected as Top Innovators to join the UpLink Innovation Network, an exclusive program tailored for Founders, CEOs, Executive Directors, and more. They will get various benefits, including access to selected events, projects, and communities led by the World Economic Forum and its partners. Participants will gain strategic connections with organizations within the Forum's and UpLink's networks, fostering valuable collaborations. The program extends targeted support encompassing technical, business, and operational guidance. Notably, a financial incentive is provided – among the selected Top Innovators, up to 10 can each receive 175,000 CHF from a total fund of 1.75 million CHF.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL enterprise has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCL Technologies and HCL Healthcare. The enterprise generates annual revenues of over US$12.8 billion with over 223,438 employees operating across 60 countries. For further information, visit www.hcl.com
About UpLink
UpLink is the open innovation platform of the World Economic Forum, dedicated to unlocking an ‘entrepreneur revolution’ to support positive systemic change for people and planet. Launched at the Forum’s Annual Meeting in Davos in January 2020 in collaboration with Salesforce and Deloitte, UpLink is now a thriving ecosystem of 400+ Top Innovators, investors, experts, and organizations, who are driving positive impact for the UN Sustainable Development Goals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230821935081/en/
Contact information
Dr. Pooja Arora | pooja_sikka@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
